aspirin has been researched along with Varicose Ulcer in 21 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Varicose Ulcer: Skin breakdown or ulceration in the drainage area of a VARICOSE VEIN, usually in the leg.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to determine the effect of low-dose aspirin on venous leg ulcer healing when used in addition to compression." | 9.22 | Low-dose aspirin as an adjuvant treatment for venous leg ulceration: study protocol for a randomized controlled trial (Aspirin4VLU). ( Bullen, C; Jull, A; Kerse, N; Parag, V; Wadham, A; Waters, J, 2016) |
| "To determine the effect of aspirin on ulcer healing rate in patients with chronic venous insufficiency, and to establish prognostic factors that influence ulcer evolution." | 9.16 | Influence of aspirin therapy in the ulcer associated with chronic venous insufficiency. ( Antonio, J; del Río Solá, ML; Fajardo, G; Vaquero Puerta, C, 2012) |
| "The aim of this study was to determine the effect of low-dose aspirin on venous leg ulcer healing when used in addition to compression." | 5.22 | Low-dose aspirin as an adjuvant treatment for venous leg ulceration: study protocol for a randomized controlled trial (Aspirin4VLU). ( Bullen, C; Jull, A; Kerse, N; Parag, V; Wadham, A; Waters, J, 2016) |
| "To determine the effect of aspirin on ulcer healing rate in patients with chronic venous insufficiency, and to establish prognostic factors that influence ulcer evolution." | 5.16 | Influence of aspirin therapy in the ulcer associated with chronic venous insufficiency. ( Antonio, J; del Río Solá, ML; Fajardo, G; Vaquero Puerta, C, 2012) |
| " We conducted 31 semi-structured telephone interviews of patients who participated in the Aspirin in Venous Leg Ulcer (ASPiVLU) randomised controlled trail (RCT) or ASPiVLU cohort study." | 3.96 | Rationale for participation in venous leg ulcer clinical research: Patient interview study. ( Richards, C; Team, V; Turnour, L; Weller, CD, 2020) |
| "Aspirin is an inexpensive, widely used medication but its safety and efficacy in the treatment of VLUs remains to be established." | 2.87 | AVURT: aspirin versus placebo for the treatment of venous leg ulcers - a Phase II pilot randomised controlled trial. ( Bland, M; Buckley, H; Chetter, I; Clark, L; Cook, L; Dumville, J; Fenner, C; Forsythe, R; Gabe, R; Harding, K; Hinchliffe, R; Layton, A; Lindsay, E; McDaid, C; Moffatt, C; Rolfe, D; Sbizzera, I; Stansby, G; Tilbrook, H; Torgerson, D; Vowden, P; Williams, L, 2018) |
| "Secondary outcomes are ulcer recurrence, wound pain, quality of life and wellbeing, adherence to study medication, adherence to compression therapy, serum inflammatory markers, hospitalisations, and adverse events at 24 weeks." | 2.82 | Aspirin in venous leg ulcer study (ASPiVLU): study protocol for a randomised controlled trial. ( Aldons, P; Barker, A; Dapiran, E; Darby, I; Haines, T; Loveland, P; Madan, JJ; McNeil, J; Sinha, S; Underwood, M; Vicaretti, M; Ward, S; Weller, CD; Wolfe, R; Woodward, M, 2016) |
| "Aspirin is an inexpensive, widely used medication but its safety and efficacy in the treatment of VLUs remains to be established." | 2.80 | Aspirin for Venous Ulcers: Randomised Trial (AVURT): study protocol for a randomised controlled trial. ( Bland, M; Buckley, H; Chetter, I; Clark, L; Cook, L; Dumville, J; Forsythe, RO; Gabe, R; Harding, K; Hinchliffe, RJ; Layton, A; Lindsay, E; McDaid, C; Moffatt, C; Phillips, C; Rolfe, D; Stansby, G; Tilbrook, H; Torgerson, D; Vowden, P; Williams, L, 2015) |
| "An increased rate of venous ulcer healing with the use of oral enteric-coated aspirin (300 mg) daily has been reported." | 2.68 | The effect of aspirin on haemostatic activity in the treatment of chronic venous leg ulceration. ( Davies, JA; Goodfield, MJ; Ibbotson, SH; Layton, AM, 1995) |
| "Aspirin is a generally well-tolerated drug that is now widely used in aged patients for its antithrombotic action." | 2.55 | Aspirin treatment for chronic wounds: Potential beneficial and inhibitory effects. ( Darby, IA; Weller, CD, 2017) |
| "Venous ulcers affect approximately 1% of the world's population, increasing healthcare expenditures and decreasing quality of life." | 2.43 | Venous ulcers: pathophysiology and treatment options. ( Eaglstein, WH; Falabella, A; Kirsner, RS; Trent, JT, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 12 (57.14) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Weller, CD | 5 |
| Richards, C | 1 |
| Turnour, L | 1 |
| Team, V | 1 |
| Martin, C | 1 |
| Bouguettaya, A | 1 |
| Underwood, M | 2 |
| Barker, AL | 1 |
| Haines, T | 2 |
| Pouniotis, D | 1 |
| Wolfe, R | 2 |
| Jull, A | 2 |
| Wadham, A | 2 |
| Bullen, C | 2 |
| Parag, V | 2 |
| Kerse, N | 2 |
| Waters, J | 2 |
| Bundrick, JB | 1 |
| Litin, SC | 1 |
| Tilbrook, H | 2 |
| Clark, L | 2 |
| Cook, L | 2 |
| Bland, M | 2 |
| Buckley, H | 2 |
| Chetter, I | 2 |
| Dumville, J | 2 |
| Fenner, C | 1 |
| Forsythe, R | 1 |
| Gabe, R | 2 |
| Harding, K | 2 |
| Layton, A | 2 |
| Lindsay, E | 2 |
| McDaid, C | 2 |
| Moffatt, C | 2 |
| Rolfe, D | 2 |
| Sbizzera, I | 1 |
| Stansby, G | 2 |
| Torgerson, D | 2 |
| Vowden, P | 2 |
| Williams, L | 2 |
| Hinchliffe, R | 1 |
| Helen, T | 1 |
| Liz, C | 1 |
| Laura, C | 1 |
| Illary, S | 1 |
| Martin, B | 1 |
| Hannah, B | 1 |
| Ian, C | 1 |
| Jo, D | 1 |
| Chris, F | 1 |
| Rachael, F | 1 |
| Rhian, G | 1 |
| Keith, H | 1 |
| Alison, L | 1 |
| Ellie, L | 1 |
| Catriona, MD | 1 |
| Christine, M | 1 |
| Debbie, R | 1 |
| Gerard, S | 1 |
| David, T | 1 |
| Peter, V | 1 |
| Laurie, W | 1 |
| Robert, H | 1 |
| Varatharajan, L | 1 |
| Thapar, A | 1 |
| Davies, AH | 1 |
| Forsythe, RO | 1 |
| Phillips, C | 1 |
| Hinchliffe, RJ | 1 |
| de Oliveira Carvalho, PE | 1 |
| Magolbo, NG | 1 |
| De Aquino, RF | 1 |
| Barker, A | 1 |
| Darby, I | 1 |
| Ward, S | 1 |
| Aldons, P | 1 |
| Dapiran, E | 1 |
| Madan, JJ | 1 |
| Loveland, P | 1 |
| Sinha, S | 1 |
| Vicaretti, M | 1 |
| Woodward, M | 1 |
| McNeil, J | 1 |
| Darby, IA | 1 |
| del Río Solá, ML | 1 |
| Antonio, J | 1 |
| Fajardo, G | 1 |
| Vaquero Puerta, C | 1 |
| Trent, JT | 1 |
| Falabella, A | 1 |
| Eaglstein, WH | 1 |
| Kirsner, RS | 1 |
| Ibbotson, SH | 2 |
| Layton, AM | 2 |
| Davies, JA | 2 |
| Goodfield, MJ | 2 |
| Ruckley, CV | 1 |
| Prescott, RJ | 1 |
| Marshall, RE | 1 |
| Tyrrell, MR | 1 |
| Renton, EJ | 1 |
| Michaëlsson, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Low Dose Aspirin for Venous Leg Ulcers: a Randomised Trial[NCT02158806] | Phase 3 | 251 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Aspirin for Venous Ulcers: Randomised Trial (AVURT)[NCT02333123] | Phase 2 | 26 participants (Actual) | Interventional | 2015-07-10 | Terminated (stopped due to Recruitment halted following TSC meeting due to poor recruitment and study unlikely to complete. Funders withdrew continued support) | ||
| Non-invasive Measurement of Microvascular Blood Flow During Mild External Compression of the Leg[NCT01804478] | 20 participants (Actual) | Interventional | 2005-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in estimated ulcer area from baseline to 24 weeks (NCT02158806)
Timeframe: Baseline, 24 weeks
| Intervention | square centimetres (Mean) |
|---|---|
| Aspirin | 4.1 |
| Placebo | 4.8 |
Mean difference in change measured by EuroQol 5D (EQ5D 3L) from baseline to 24 weeks. Crude health state scores for each group are not shown (health state is scored 0 to 100 at baseline and 24 weeks); higher mean differences in change from baseline to 24 weeks within groups indicate greater change on health state for that group. (NCT02158806)
Timeframe: Baseline, 24 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Aspirin | 7.4 |
| Placebo | 4.0 |
Adherence to study medication as measured by pill counts (agreement between expected number of tablets remaining after healing and days to healing) (NCT02158806)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 92 |
| Placebo | 92 |
Number of participants in each arm with completely healed reference ulcers at 24 weeks (NCT02158806)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 88 |
| Placebo | 101 |
Time to event (complete healing defined as intact skin with absence of scab) (NCT02158806)
Timeframe: 24 weeks
| Intervention | days (Median) |
|---|---|
| Aspirin | 77 |
| Placebo | 69 |
Mean difference in change in Charing Cross Venous Ulcer Questionnaire (CXVUQ)) from baseline to 24 weeks. Crude subscale scores for each group are not shown (each crude subscale is scored 0 to 100 at baseline and 24 weeks); higher mean differences in change from baseline to 24 weeks within groups indicate greater change on the subscales for that group. (NCT02158806)
Timeframe: 24 weeks
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Social function | Domestic activities | Cosmesis | Emotional status | Overall | |
| Aspirin | -6.2 | -6.6 | -6.1 | -9.4 | -7.3 |
| Placebo | -4.7 | -5.2 | -4.9 | -6.5 | -5.5 |
Mean difference in change in Short Form 36 (SF36) from baseline to 24 weeks. Crude subscale scores for each group are not shown (each crude subscale is scored 0 to 100 at baseline and 24 weeks); higher mean differences in change from baseline to 24 weeks within groups indicate greater change on the subscales for that group. (NCT02158806)
Timeframe: Baseline, 24 weeks
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Physical Functioning | Role Physical | Bodily Pain | General Health | Vitality | Social Functioning | Role Emotional | Mental Health | |
| Aspirin | 5.0 | 11.7 | 11.4 | -1.1 | 3.9 | 5.8 | 10.5 | -1.2 |
| Placebo | 3.8 | 10.3 | 9.0 | -0.8 | -0.3 | 4.9 | 6.8 | 1.2 |
5 reviews available for aspirin and Varicose Ulcer
| Article | Year |
|---|---|
Clinical pearls in general internal medicine.
Topics: Adult; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Calcium; Cardiac Tamponade; Clavicle | 2018 |
Oral aspirin for treating venous leg ulcers.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Compression Bandages; | 2016 |
Aspirin treatment for chronic wounds: Potential beneficial and inhibitory effects.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Cyclooxygenase Inhibitor | 2017 |
Venous ulcers: pathophysiology and treatment options.
Topics: Anti-Inflammatory Agents; Aspirin; Bandages; Chronic Disease; Debridement; Diosmin; Growth Substance | 2005 |
Pharmacological treatments for venous leg ulcers.
Topics: Anabolic Agents; Aspirin; Cinnarizine; Fibrinolytic Agents; Histamine H1 Antagonists; Humans; Pentox | 1999 |
10 trials available for aspirin and Varicose Ulcer
| Article | Year |
|---|---|
Once daily 300 mg aspirin with compression versus compression alone in patients with chronic venous leg ulcers (ASPiVLU): A randomised, double-blinded, multicentre, placebo-controlled, clinical trial.
Topics: Adult; Aspirin; Compression Bandages; Humans; Prospective Studies; Varicose Ulcer; Wound Healing | 2021 |
Low dose aspirin as adjuvant treatment for venous leg ulceration: pragmatic, randomised, double blind, placebo controlled trial (Aspirin4VLU).
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Aspirin; Dose-Response Relationship, Drug; Double-Blind Method | 2017 |
AVURT: aspirin versus placebo for the treatment of venous leg ulcers - a Phase II pilot randomised controlled trial.
Topics: Aged; Aspirin; Chronic Disease; Compression Bandages; Double-Blind Method; Female; Humans; Male; Mid | 2018 |
Aspirin versus placebo for the treatment of venous leg ulcers-a phase II, pilot, randomised trial (AVURT).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Compression Bandages; Double-Blind M | 2019 |
Aspirin for Venous Ulcers: Randomised Trial (AVURT): study protocol for a randomised controlled trial.
Topics: Aspirin; Chronic Disease; Clinical Protocols; Combined Modality Therapy; Compression Bandages; Doubl | 2015 |
Low-dose aspirin as an adjuvant treatment for venous leg ulceration: study protocol for a randomized controlled trial (Aspirin4VLU).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Compression Bandages; Cost-Benefit Analysis; Dose-Response | 2016 |
Aspirin in venous leg ulcer study (ASPiVLU): study protocol for a randomised controlled trial.
Topics: Aspirin; Australia; Clinical Protocols; Combined Modality Therapy; Cyclooxygenase Inhibitors; Double | 2016 |
Influence of aspirin therapy in the ulcer associated with chronic venous insufficiency.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Bandages, Hydrocolloid; Cardiovascular Agents; Chi-Square D | 2012 |
The effect of aspirin on haemostatic activity in the treatment of chronic venous leg ulceration.
Topics: Aspirin; Double-Blind Method; Factor VIII; Female; Fibrinogen; Hemostasis; Humans; Male; Plasminogen | 1995 |
Randomised trial of oral aspirin for chronic venous leg ulcers.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Bandages; Chronic Disease; Combined Modality | 1994 |
6 other studies available for aspirin and Varicose Ulcer
| Article | Year |
|---|---|
Rationale for participation in venous leg ulcer clinical research: Patient interview study.
Topics: Aged; Aged, 80 and over; Aspirin; Female; Humans; Leg Ulcer; Male; Middle Aged; Motivation; Patient | 2020 |
Adjunctive aspirin for venous ulcer healing.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Varicose Ulcer | 2014 |
Aspirin can aid bandage as the best treatment for leg ulcers.
Topics: Aspirin; Compression Bandages; Humans; Leg Ulcer; Varicose Ulcer; Wound Healing | 2016 |
Treatment of chronic leg ulcers.
Topics: Aspirin; Bandages; Chronic Disease; Clinical Trials as Topic; Combined Modality Therapy; Data Interp | 1994 |
Treatment of chronic leg ulcers.
Topics: Aspirin; Bandages; Chronic Disease; Clinical Trials as Topic; Combined Modality Therapy; Humans; Var | 1994 |
Effects of antihistamines, acetylsalicylic acid and prednisone on cutaneous reactions to kallikrein and prostaglandin E1.
Topics: Adult; Aspirin; Bradykinin; Chronic Disease; Cyproheptadine; Drug Hypersensitivity; Eczema; Female; | 1970 |